The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Managing the primary tumor in patients with rectal cancer and synchronous liver metastases: The role of organ preservation.
 
Galen Gist
No Relationships to Disclose
 
Antony Haddad
No Relationships to Disclose
 
Kever Lewis
No Relationships to Disclose
 
Tsuyoshi Konishi
No Relationships to Disclose
 
George Chang
Consulting or Advisory Role - Medicaroid
 
Michael White
No Relationships to Disclose
 
Craig Messick
No Relationships to Disclose
 
Oliver Peacock
No Relationships to Disclose
 
Ching-Wei Tzeng
Honoraria - PanTher Therapeutics
Research Funding - Sirtex Medical (Inst)
 
Hop Tran Cao
No Relationships to Disclose
 
Jesse Joshua Smith
Consulting or Advisory Role - BioNTech SE; Foundation Medicine; Gerson Lehrman Group; GlaxoSmithKline; Guardant Health; Regeneron; Urogen pharma
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - Johnson & Johnson/Janssen
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis
 
Christine Parseghian
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen
Research Funding - BioMed Valley Discoveries; Lilly; Verastem
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Van Morris
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Exelixis; GlaxoSmithKline; Incyte; Pfizer
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Jean-Nicolas Vauthey
No Relationships to Disclose
 
Y. Nancy You
No Relationships to Disclose
 
Timothy Newhook
No Relationships to Disclose
 
Neal Bhutiani
Patents, Royalties, Other Intellectual Property - Patent US20250099543A1 -- Compositions and methods for the treatment of cancer and/or inflammatory diseases are provided. A combination of interleukin-10 (IL-10) and interleukin-12 (IL-12) is used to treat cancer and/or inflammatory diseases, and a combin (Inst)